Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful desensitization protocol for hypersensitivity reaction probably caused by dabrafenib in a patient with metastatic melanoma.

Japanese journal of clinical oncology - 1 Sept 2015

Bar-Sela Gil, Abu-Amna Mahmoud, Hadad Salim, Haim Nissim, Shahar Eduardo

Abstract excerpt

Vemurafenib and dabrafenib are both orally bioavailable small molecule agents that block mitogen activated protein kinase signalling in patients with melanoma and BRAF(V600E) mutation. Generalized hypersensitivity reactions to vemurafenib or dabrafenib have not been described. Continuing vemurafenib or dabrafenib therapy despite hypersensitivity reaction is especially important in patients with melanoma and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents
Share to Desensitization, Immunologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Drug Hypersensitivity

Share to Gamma Rays

Share to Imidazoles

Share to Oximes

Share to Positron-Emission Tomography

Source

Identifiers

PMID: 26056325
DOI: 10.1093/jjco/hyv086

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful desensitization protocol for hypersensitivity reaction probably caused by dabrafenib in a patient with metastatic melanoma.PMID 26056325Read ↗

Successful Dabrafenib Desensitization Protocols in a Patient with Metastatic Melanoma.Semantic proximity Read ↗

Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.Semantic proximity Read ↗

Dabrafenib desensitization after a vemurafenib-induced hypersensitivity reaction in a pediatric patient with BRAFV600E mutant pilocytic astrocytomaSemantic proximity Read ↗

Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches.Semantic proximity Read ↗

Successful desensitization under antihistamine suppression in a case with urticaria due to osimertinib.Semantic proximity Read ↗

Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.Semantic proximity Read ↗

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.Semantic proximity Read ↗

Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitorSemantic proximity Read ↗

Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer.Semantic proximity Read ↗

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.Semantic proximity Read ↗

The First Successful Desensitization Protocol in Exenatide Allergy: A Case ReportSemantic proximity Read ↗

Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.